RhumbLine Advisers
ALDX icon

RhumbLine Advisers’s Aldeyra Therapeutics ALDX Stock Holding History

RhumbLine Advisers’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-26,652
Closed -$56.8K – 4048
2026
Q2 		$56.8K Sell
26,652
-42,553
-61% -$73.1K ﹤0.01% 3658
2026
Q1 		$117K Sell
69,205
-1,208
-2% -$5.29K ﹤0.01% 3342
2025
Q4 		$365K Sell
70,413
-8,233
-10% -$42.3K ﹤0.01% 2862
2025
Q3 		$411K Buy
78,646
+1,152
+1% +$6.01K ﹤0.01% 2823
2025
Q2 		$297K Buy
77,494
+2,018
+3% +$5.22K ﹤0.01% 2991
2025
Q1 		$434K Sell
75,476
-2,712
-3% -$16K ﹤0.01% 2661
2024
Q4 		$390K Buy
78,188
+1,087
+1% +$5.58K ﹤0.01% 2825
2024
Q3 		$416K Buy
77,101
+120
+0.2% +$571 ﹤0.01% 2831
2024
Q2 		$255K Buy
76,981
+12,907
+20% +$50.5K ﹤0.01% 3089
2024
Q1 		$210K Buy
64,074
+2,211
+4% +$7.27K ﹤0.01% 3153
2023
Q4 		$217K Sell
61,863
-649
-1% -$2K ﹤0.01% 3147
2023
Q3 		$418K Buy
62,512
+3,018
+5% +$22.4K ﹤0.01% 2718
2023
Q2 		$499K Buy
+59,494
New +$586K ﹤0.01% 2685
2022
Q2 		– Sell
-47,596
Closed -$212K – 3092
2022
Q1 		$212K Buy
47,596
+4,996
+12% +$19.9K ﹤0.01% 2741
2021
Q4 		$170K Sell
42,600
-853
-2% -$6.51K ﹤0.01% 2868
2021
Q3 		$382K Buy
43,453
+1,923
+5% +$17.6K ﹤0.01% 2672
2021
Q2 		$471K Buy
+41,530
New +$499K ﹤0.01% 2589
2020
Q2 		– Sell
-30,784
Closed -$76K – 3061
2020
Q1 		$76K Hold
30,784
– – ﹤0.01% 2823
2019
Q4 		$179K Buy
30,784
+143
+0.5% +$826 ﹤0.01% 2779
2019
Q3 		$161K Buy
30,641
+706
+2% +$3.8K ﹤0.01% 2799
2019
Q2 		$180K Buy
29,935
+2,752
+10% +$20.7K ﹤0.01% 2817
2019
Q1 		$245K Buy
27,183
+4,010
+17% +$34.1K ﹤0.01% 2652
2018
Q4 		$192K Buy
23,173
+9,260
+67% +$94.9K ﹤0.01% 2748
2018
Q3 		$192K Sell
13,913
-343
-2% -$2.78K ﹤0.01% 2738
2018
Q2 		$113K Buy
+14,256
New +$114K ﹤0.01% 2859

Other funds holding ALDX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $234B AUM 43.58% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

RhumbLine Advisers's ALDX Position: Q3 2026 in Review

RhumbLine Advisers sold out of Aldeyra Therapeutics (ALDX) in Q3 2026, closing a stake of 26,652 shares — an estimated $56.8K sold.

RhumbLine Advisers first reported a position in ALDX in Q2 2018 and held it in 25 quarters. The position peaked at $499K in Q2 2023. 63 funds tracked by Wall St. Rank hold ALDX as of Q3 2026.

  • RhumbLine Advisers reported no remaining Aldeyra Therapeutics position as of Q3 2026 after selling out during the quarter.
  • RhumbLine Advisers sold 26,652 Aldeyra Therapeutics shares in Q3 2026, an estimated $56.8K.
  • RhumbLine Advisers first reported a position in Aldeyra Therapeutics in Q2 2018 and held it in 25 quarters.
  • RhumbLine Advisers's Aldeyra Therapeutics position peaked at $499K in Q2 2023.
  • 63 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.